Jung Eun-kyung "Continuing Final Contract Negotiations with Moderna... Announcement Upon Completion" (Update)

COVAX Facility Q1 Introduction Negotiations Underway

[Image source=Yonhap News]

[Asia Economy Reporter Seo So-jeong] The government is continuing negotiations ahead of the final contract with the U.S. pharmaceutical company Moderna to secure 20 million doses of the COVID-19 vaccine. The government plans to promptly announce the contract details once the negotiations are finalized.

Jung Eun-kyung, head of the Central Disease Control Headquarters, stated at the regular briefing on the 31st, "We are continuing to review and negotiate the contract with Moderna," adding, "There has been progress on most of the negotiation points, and once the negotiations are concluded, we will organize the details and promptly inform you."

Regarding the procurement of 10 million doses of vaccine through the joint vaccine purchase and distribution project 'COVAX Facility (COVAX),' Director Jung explained, "We already made an advance payment and signed the agreement on October 9," and added, "The Global Alliance for Vaccines and Immunization (GAVI), which is responsible for vaccine supply, held a briefing on December 18 stating that supply would begin in the first quarter."

Director Jung said, "We are currently negotiating the volume that can be supplied in the first quarter through GAVI," and continued, "We have received some proposals for vaccine products, expressed our intention to purchase them, and are continuing discussions on the specific quantities and supply schedule."

He added, "This is not only a negotiation with our country but also requires coordination among various countries participating in COVAX to determine the allocation and supply timing of the doses," and said, "From the government's standpoint, we are continuing negotiations to ensure rapid receipt of doses in the first quarter, and we will inform you again once it is confirmed."

This content was produced with the assistance of AI translation services.